Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nebivolol: new therapy update.

Sachin S Sule1, William Frishman

  • 1Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York, USA.

Cardiology in Review
|August 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Celiac Disease and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Challenges.

Cardiology in review·2026
Same author

Cardiovascular Dysautonomia and Sudden Cardiac Death in Parkinson's Disease: Emerging Clinical Insights and Implications for Care.

Cardiology in review·2026
Same author

From Mobile Army Surgical Hospital Units to Street Medicine: Implications for Veterans Experiencing Homelessness.

Military medicine·2026
Same author

Coronary Microvascular Dysfunction in Cardiovascular Disease: Diagnosis and Management.

Cardiology in review·2026
Same author

Shock: Pathophysiology, Classification, and the Role of Lactate in Diagnosis and Prognosis.

Cardiology in review·2026
Same author

Coronary Artery Spasm: Pathophysiology, Diagnosis, and Clinical Implications.

Cardiology in review·2026
Same journal

Beta-Blockers Versus Flecainide for Atrial Fibrillation: A First-Line Strategy Review of Efficacy, Safety, and Patient Selection.

Cardiology in review·2026
Same journal

Cerebrovascular Disease in Pregnancy: Epidemiology, Pathophysiology, Risk Factors, Diagnostic and Management Considerations, Long-Term Maternal Outcomes: A Narrative Review.

Cardiology in review·2026
Same journal

Immunometabolism in Cardiovascular Disease: Linking Metabolic Reprogramming to Inflammation, Atherothrombosis, and Clinical Outcomes.

Cardiology in review·2026
Same journal

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same journal

Valve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
See all related articles

Nebivolol, a novel beta-blocker, effectively lowers blood pressure and shows promise for treating hypertension and heart failure. Its unique properties offer comparable or better tolerability than existing medications.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Nebivolol is a beta-blocker being reviewed by the U.S. Food and Drug Administration for hypertension treatment.
  • It possesses high beta-1 receptor specificity and nitric oxide-mediated vasodilation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of nebivolol in hypertension and heart failure.
  • To compare nebivolol's effects with existing antihypertensive and heart failure medications.

Main Methods:

  • Clinical trials comparing nebivolol to placebo and other agents like atenolol, bisoprolol, amlodipine, nifedipine, lisinopril, and hydrochlorothiazide.
  • Studies assessed blood pressure reduction, tolerability, and outcomes in elderly patients with heart failure.

Main Results:

Related Experiment Videos

  • Nebivolol significantly reduces blood pressure compared to placebo.
  • Its efficacy and tolerability are similar or superior to comparator drugs.
  • In elderly heart failure patients, nebivolol improved survival and reduced hospital admissions.

Conclusions:

  • Nebivolol demonstrates potential as an effective treatment for hypertension and heart failure.
  • Further research is warranted for its use in patients with coronary artery disease.